NCT04147234: A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have at least one tumor lesion which is suitable for injection & a second tumor lesion which is suitable for biopsy

Comments are closed.

Up ↑